Last month, a new drug for Alzheimer's disease, Leqembi, was approved in Korea. Leqembi, which was developed by Eisai and Biogen, targets the amyloid beta (Aβ) protein in the brain, which is considered one of the most likely causes of Alzheimer's disease.

The industry welcomed Leqembi’s arrival because there had been no promising new drugs to treat Alzheimer's disease until now.

Until now, donepezil, galantamine, rivastigmine, and memantine were used for Alzheimer's, but all were only able to relieve symptoms such as cognitive impairment and do not fundamentally treat dementia.

Since then, a number of brain function improvement drugs have been introduced to prevent Alzhe